Effects of flaxseed and hesperidin in patients with prediabetes

Effects of concomitant administration of flaxseed and hesperidin on cardiac and metabolic parameters in patients with prediabetes

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181120041710N2

Enrollment

Registered

2020-02-10

Start date

2018-01-01

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prediabetes. Impaired fasting glucose

Interventions

Intervention 1: Intervention group: lifestyle modification plus combination therapy of brown flaxseed (30 g milled) and hesperidin (two 500 mg capsules). Also, patients were instructed to divide suppl

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Aged 18 to 70 years Diagnosed with prediabetes Having body mass index (BMI) range of 25 to 40 kg/m2

Exclusion criteria

Exclusion criteria: History of cardiovascular, pulmonary, renal, hepatic and gastrointestinal disease Taking anti-hypertensive, glucose-lowering medications, lipid-modifying agents and omega-3 dietary supplement Being under treatment with steroids and nonsteroidal anti-inflammatory drugs Being on a calorie-restricted regimen within 3 months before the commencement of the trial Being pregnant or lactating

Design outcomes

Primary

Measure	Time frame
Weight. Timepoint: Baseline and Week 12. Method of measurement: Scale.;Waist circumference. Timepoint: Baseline and Week 12. Method of measurement: Meter.;Blood pressure. Timepoint: Baseline and Week 12. Method of measurement: Mercury Sphygmomanometer.;Serum concentration of fasting blood sugar. Timepoint: Baseline and Week 12. Method of measurement: Enzymatic method.;Serum concentration of fasting blood insulin. Timepoint: Baseline and Week 12. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Serum concentration of triglyceride. Timepoint: Baseline and Week 12. Method of measurement: Enzymatic method.;Serum concentration of HDL. Timepoint: Baseline and Week 12. Method of measurement: Enzymatic method.;Serum concentration of LDL. Timepoint: Baseline and Week 12. Method of measurement: Enzymatic method.;Serum concentration of hs-CRP. Timepoint: Baseline and Week 12. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Serum concentration of TNF-alpha. Timepoint: Baseline and Week 12. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).	—

Measure

Time frame

Weight. Timepoint: Baseline and Week 12. Method of measurement: Scale.;Waist circumference. Timepoint: Baseline and Week 12. Method of measurement: Meter.;Blood pressure. Timepoint: Baseline and Week 12. Method of measurement: Mercury Sphygmomanometer.;Serum concentration of fasting blood sugar. Timepoint: Baseline and Week 12. Method of measurement: Enzymatic method.;Serum concentration of fasting blood insulin. Timepoint: Baseline and Week 12. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Serum concentration of triglyceride. Timepoint: Baseline and Week 12. Method of measurement: Enzymatic method.;Serum concentration of HDL. Timepoint: Baseline and Week 12. Method of measurement: Enzymatic method.;Serum concentration of LDL. Timepoint: Baseline and Week 12. Method of measurement: Enzymatic method.;Serum concentration of hs-CRP. Timepoint: Baseline and Week 12. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Serum concentration of TNF-alpha. Timepoint: Baseline and Week 12. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Yari

Shahid Beheshti University of Medical Sciences

zahrayari_nut@yahoo.com+98 21 2235 7483

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026